November 2013 Weekly Bytes

Weekly Byte

Abstract:Background: Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients...

Weekly Byte

France's world share of science and social-science papers over a recent five-year period, ranked according to percentage of papers in each of 21 main fields indexed by Thomson Reuters. Also,...